DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Candriam S.C.A.

Candriam S.C.A. reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 78.0% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 50,610 shares of the medical device company’s stock after selling 179,841 shares during the quarter. Candriam S.C.A.’s holdings in DexCom were worth $3,936,000 as of its most recent filing with the SEC.

Several other institutional investors also recently bought and sold shares of DXCM. Forvis Mazars Wealth Advisors LLC boosted its position in shares of DexCom by 0.7% during the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock worth $1,359,000 after purchasing an additional 118 shares in the last quarter. Principal Securities Inc. boosted its position in shares of DexCom by 3.4% during the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after purchasing an additional 135 shares in the last quarter. Crossmark Global Holdings Inc. boosted its position in shares of DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock worth $1,259,000 after purchasing an additional 182 shares in the last quarter. GPS Wealth Strategies Group LLC boosted its position in shares of DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock worth $123,000 after purchasing an additional 185 shares in the last quarter. Finally, Peterson Wealth Services boosted its position in shares of DexCom by 7.1% during the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock worth $236,000 after purchasing an additional 201 shares in the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several brokerages have commented on DXCM. Citigroup boosted their target price on shares of DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research report on Tuesday, March 4th. Wells Fargo & Company boosted their price objective on shares of DexCom from $90.00 to $94.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 11th. Morgan Stanley boosted their price objective on shares of DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Canaccord Genuity Group boosted their price objective on shares of DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research report on Friday, February 14th. Finally, Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their price objective for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $99.82.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the transaction, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This represents a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 38,083 shares of company stock valued at $3,309,794 in the last 90 days. 0.30% of the stock is currently owned by insiders.

DexCom Trading Down 2.1 %

NASDAQ DXCM opened at $77.84 on Friday. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00. The company has a 50-day moving average of $84.83 and a 200-day moving average of $76.99. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The company has a market cap of $30.42 billion, a P/E ratio of 54.43, a P/E/G ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 EPS for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.